Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ian Read
AddedFeb 13, 2024
UpdatedMay 31, 2026
Ian Read

Ian Read

Board Member, DXC

CrunchbaseLinkedIn

Ian Read's Career

DXC
DXC

Virginia, US

Board Member· Board
Pfizer
Pfizer

New York, NY, US

Board Member· Board
Partnership for New York City
Partnership for New York City

New York City, NY, US

Board Member· Board
Areteia Therapeutics
Areteia Therapeutics

Short Hills, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ian Read's Career

DXC
DXC
Public115k2017Virginia, US
Board Member· Board

Recent news

DXC Technology Reports Third Quarter Fiscal Year 2026 ResultsDXC Investor Relations · 2026
DXC Technology Announces Redemption of Senior Notes Due 2026DXC Investor Relations · 2025
DXC Technology Reports Second Quarter Fiscal Year 2026 ResultsDXC Investor Relations · 2025

Leadership at DXC

Raul FernandezRaul FernandezBoard Member
Carrie TeffnerCarrie TeffnerBoard Member
Amy E. AlvingAmy E. AlvingBoard Member
Mike SalvinoMike SalvinoBoard Member
David HerzogDavid HerzogBoard Member
Robert Del BeneRobert Del BeneFounder
Pfizer
Pfizer
Public$31B83k1849New York City, NY, US
Board Member· Board

Recent news

Promise Bio exits stealth backed by Pfizer and AstraZenecaTechCrunch · 2024
Nigeria’s Remedial Health gets QED backing in $12M roundTechCrunch · 2023

Leadership at Pfizer

Suhas PrabhuSuhas PrabhuBoard Member
Scott GottliebScott GottliebBoard Member
Albert BourlaAlbert BourlaBoard Member
James QuinceyJames QuinceyBoard Member
Suzanne Nora JohnsonSuzanne Nora JohnsonBoard Member
Sarah M. WilliamsSarah M. WilliamsCo-Founder
Partnership for New York City
Partnership for New York City
Fund621979New York City, NY, US
Board Member· Board

Leadership at Partnership for New York City

Henry KravisHenry KravisBoard Member
Frank BisignanoFrank BisignanoBoard Member
Jon OringerJon OringerBoard Member
Kathryn WyldeKathryn WyldeCEO
David RockefellerDavid RockefellerFounder
Jeff BlauJeff BlauBoard Member
Areteia Therapeutics
Areteia Therapeutics
Series A$350M302022Short Hills, NJ, US
Board Member· Board

Leadership at Areteia Therapeutics

Jorge BartolomeJorge BartolomeCEO

Ian Read's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Ian Read

Jon MoultonJon MoultonFounder · Better CapitalMartin SorrellMartin SorrellFounder · S4S VenturesMichael LiebreichMichael LiebreichCEO · BloombergnefJonathan MildenhallJonathan MildenhallBoard Member · EverlaneBen WayBen WayFounder & CEO · RainmakersGian FulgoniGian FulgoniCo-Founder · Comscore